The $50 Medicare GLP-1 vs. The $99 Compounded GLP-1: A Cost Showdown With an Expiration Date
Two seismic forces collide this summer: $50/month Medicare GLP-1s launch July 1, while the FDA moves to permanently ban compounding by June 29. Here's how the economics actually shake out.
Two Seismic Forces Collide This Summer
The most important 6 weeks in GLP-1 affordability are happening right now. On June 29, 2026, the FDA's public comment period closes on a proposal that would permanently ban large-scale compounding of semaglutide, tirzepatide, and liraglutide. Two days later, on July 1, 2026, the Medicare GLP-1 Bridge launches at $50/month for brand-name formulations.
These two events will reshape the GLP-1 cost landscape for millions of patients. Here's how they compare.
Option A: The $50 Medicare GLP-1 Bridge
| Detail | Specs |
|---|---|
| Monthly cost | $50 |
| Medications covered | Foundayo (all), Wegovy (all), Zepbound (KwikPen only) |
| Who qualifies | Medicare Part D beneficiaries (PDP, MA-PD, SNP, EGWP, LI NET) |
| Prior authorization | Required (criteria TBD) |
| Duration | July 1, 2026 – December 31, 2027 |
| Supply | FDA-approved branded medications (no risk of enforcement action) |
| Clinical monitoring | Through your prescribing physician |
Option B: Compounded GLP-1s (While They Last)
| Detail | Specs |
|---|---|
| Monthly cost | $99–350 (varies by provider) |
| Medications available | Compounded semaglutide, tirzepatide |
| Who qualifies | Anyone with a prescription (no insurance needed) |
| Prior authorization | Not required |
| Duration | Uncertain — FDA 503B exclusion could end it permanently |
| Regulatory status | At risk |
| Clinical monitoring | Varies by provider (some excellent, some minimal) |
Head-to-Head Cost Analysis
| Scenario | Medicare Bridge | Compounded (Avg.) | Winner |
|---|---|---|---|
| Monthly cost | $50 | $150–300 | Medicare |
| Annual cost | $600 | $1,800–3,600 | Medicare |
| Access barrier | Prior auth + eligible plan type | Prescription only | Compounded |
| Medication quality | FDA-approved branded | Pharmacy-compounded | Medicare |
| Long-term availability | Guaranteed through Dec 2027 | Could end any day | Medicare |
| Age restriction | 65+ (Medicare eligible) | None | Compounded |
The FDA's proposal to add semaglutide, tirzepatide, and liraglutide to the 503B Bulks List exclusion would permanently foreclose large-scale compounding — even if future shortages occur. Public comments are being accepted through June 29, 2026. If finalized, patients currently on compounded GLP-1s will need to transition to brand-name formulations.
Which Path Is Right for You?
| You Are… | Best Path |
|---|---|
| Medicare beneficiary with Part D | Medicare Bridge ($50/mo) — no contest |
| Under 65, no insurance | Compounded while available, with transition plan to Foundayo or branded options |
| Under 65, with commercial insurance | Check manufacturer savings programs first (NovoCare, LillyDirect), then compounded as backup |
| Currently on compounded, planning long-term | Start your brand-name transition plan now — don't wait for the FDA ruling |
Brand-name GLP-1 prescriptions — Wegovy, Zepbound, Foundayo
Sources
- CMS. "Medicare GLP-1 Bridge." cms.gov
- Pharmacy Times. "FDA Moves to Permanently Close the Door on Compounded GLP-1s." May 2026. pharmacytimes.com
- CMS. "$50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." May 2026. cms.gov